Advancing the science of early Alzheimer’s detection
Our work brings together decades of research, proprietary biomarker discovery, and next-generation assay technology to redefine how Alzheimer’s Disease is detected and understood.
SMarT Minds Dx is transforming Alzheimer’s diagnostics through blood-based biomarker technology that enables earlier detection, biological staging, and ongoing monitoring. By pairing proprietary antibodies with ultra-sensitive digital immunoassays, we will deliver clinically meaningful insights that fit seamlessly into routine pathology workflows. Our science is designed for accuracy, scale, and equitable global access.
clinical value
Technology Overview
How it works
SMarT Minds Dx integrates proprietary high-affinity antibodies with state-of-the-art digital immunoassay platforms. These assays detect low-abundance biomarkers, providing a reliable, accessible alternative to PET imaging and CSF testing.
Why this science matters
Blood-based biomarkers support earlier diagnosis, triage, and treatment selection. Clinicians gain biological clarity faster, while patients benefit from earlier intervention, improved monitoring, and reduced reliance on invasive or high-cost testing.
Steps
The Diagnostic Pathway
A simple, scalable pathway designed for real-world clinical adoption.
Sample Collection
A standard blood draw is completed at pathology collection centres – fast, accessible, and routine.
Biomarker Analysis
Proprietary SMarT antibodies measure key Alzheimer’s biomarkers allowing high-sensitivity detection.
Clinical Interpretation
Results are evaluated against validated biological thresholds to determine amyloid status, tau pathology, and disease stage.
Report Delivered
To deliver affordable, accurate, and accessible Alzheimer’s diagnostics that support earlier intervention and improve outcomes for patients and carers.
Our scientific progress
Every milestone brings us closer to a future where earlier answers and clearer guidance are available to everyone affected by Alzheimer’s Disease.
Our First Solution
A next-generation blood biomarker test for Alzheimer’s
Alzheimer’s Disease is rising fast and diagnostics options have struggled to keep pace with innovations in treatment and prevention. SMarT Minds Dx is developing a breakthrough blood-based diagnostic that enables precision on a global scale.
Early detection of Alzheimer’s pathology
Our blood test identifies a change in an early detection biomarker shifts, giving clinicians and families more time to act, plan, and intervene proactively.
Precise staging across the disease continuum
We will provide insight into the biological stage of Alzheimer’s supporting more confident clinical decision-making.
Accurate monitoring of therapeutic response
Our technology can measures changes in amyloid and tau to support treatment optimisation and personalised care.
Affordable and scalable at population level
Our blood test will remove barriers to access and allows health systems to implement equitable screening programs without the infrastructure burden of traditional tests.
Proprietary antibodies and validated science
Developed using decades of Alzheimer’s research and advanced digital immunoassay platforms.
Seamless integration into existing pathology workflows
Fits effortlessly into standard blood collection pathways, enabling thousands of clinics and laboratories to adopt Alzheimer’s diagnostics without significant operational change.